In 120 patients with mismatch repair proficient locally advanced colon cancer, neoadjuvant CAPOX/FOLFOX before surgery did not significantly improve 2-year disease-free survival vs upfront surgery plus adjuvant chemotherapy (88.9% vs 83.3%; P=0.34) in a phase II interim analysis.
RCTn = 120
Arredondo et al. ELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer